Zacks reissued their neutral rating on shares of Sanofi-Aventis (NYSE: SNY) in a report released on Friday. Zacks currently has a $52.00 target price on the stock.
Zacks’ analyst wrote, “Sanofi reported fourth quarter 2012 business earnings of $0.77 per ADS, in line with the Zacks Consensus Estimate but below the year-ago earnings of $1.05 per ADS. Fourth quarter net sales increased 0.2% on a reported basis but fell 1.7% at constant exchange rates (CER). Sanofi expects 2013 business earnings per share to be 5% lower on a year-over-year basis at CER. We expect Sanofi to continue to contain operating costs to offset the weakening sales of some of its biggest products. We also expect the company to look to grow through acquisitions. The Apr 2011 Genzyme acquisition has not only brought in additional revenues, but has also strengthened Sanofi’s pipeline. New product launches should make significant revenue contributions in the upcoming quarters. We remain Neutral on Sanofi with a target price of $52.00.”
Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a buy rating on shares of Sanofi-Aventis in a research note to investors on Friday, March 1st. Finally, analysts at Barclays Capital downgraded shares of Sanofi-Aventis from an overweight rating to an equal weight rating in a research note to investors on Tuesday, January 29th.
Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of Buy and an average price target of $52.00.
Sanofi-Aventis (NYSE: SNY) opened at 50.00 on Friday. Sanofi-Aventis has a 1-year low of $33.03 and a 1-year high of $50.93. The stock’s 50-day moving average is currently $48.39. The company has a market cap of $132.3 billion and a price-to-earnings ratio of 20.65.
Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
